key: cord-0851169-adwity4d authors: Kaulen, Leon D.; Doubrovinskaia, Sofia; Mooshage, Christoph; Jordan, Berit; Purrucker, Jan; Haubner, Carmen; Seliger, Corinna; Lorenz, Hanns‐Martin; Nagel, Simon; Wildemann, Brigitte; Bendszus, Martin; Wick, Wolfgang; Schönenberger, Silvia title: Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series date: 2021-10-31 journal: Eur J Neurol DOI: 10.1111/ene.15147 sha: 3fda43912099160840e35f91bfcf0bbe4f1a85e5 doc_id: 851169 cord_uid: adwity4d BACKGROUND AND PURPOSE: Population‐based studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines may trigger immune‐mediated thrombotic thrombocytopenia (VITT) raising concerns for other autoimmune responses. The aim was to characterize neurological autoimmunity after SARS‐CoV‐2 vaccinations. METHODS: In this single‐centre prospective case study patients with neurological autoimmunity in temporal association (≤6 weeks) with SARS‐CoV‐2 vaccinations and without other triggers are reported. Clinical, laboratory and imaging data were collected with a median follow‐up of 49 days. RESULTS: In the study period 232,603 inhabitants from the main catchment area of our hospital (Rhein‐Neckar‐Kreis, county) received SARS‐CoV‐2 vaccinations. Twenty‐one cases (new onset n = 17, flares n = 4) diagnosed a median of 11 days (range 3–23) following SARS‐CoV‐2 vaccinations (BNT162b2 n = 12, ChAdOx1 n = 8, mRNA‐1273 n = 1) were identified. Cases included VITT with cerebral venous sinus thrombosis (n = 3), central nervous system demyelinating diseases (n = 8), inflammatory peripheral neuropathies (n = 4), myositis (n = 3), myasthenia (n = 1), limbic encephalitis (n = 1) and giant cell arteritis (n = 1). Patients were predominantly female (ratio 3.2:1) and the median age at diagnosis was 50 years (range 22–86). Therapy included administration of steroids (n = 15), intravenous immunoglobulins in patients with Guillain–Barré syndrome or VITT (n = 4), plasma exchange in cases unresponsive to steroids (n = 3) and anticoagulation in VITT. Outcomes were favourable with partial and complete remissions achieved in 71% and 24%, respectively. Two patients received their second vaccination without further aggravation of autoimmune symptoms under low‐dose immunosuppressants. CONCLUSIONS: In this study various neurological autoimmune disorders encountered following SARS‐CoV‐2 vaccinations are characterized. Given the assumed low incidence and mostly favourable outcome of autoimmune responses, the benefits of vaccinations outweigh the comparatively small risks. ChAdOx1 nCov-19, Janssen/Johnson&Johnson Ad26.COV2.S) [1] [2] [3] [4] . Overall, severe neurological complications including autoimmune disorders affecting the nervous system are exceedingly rare (<0.1%) following SARS-CoV-2 vaccinations [1] [2] [3] [4] . With the exception of the Ad26.COV2.S study, patients with autoimmunity or those receiving systemic immunosuppressive treatment were excluded from these initial clinical trials [3] . Therefore, limited safety data have been generated in this particular patient cohort. However, vaccinations are particularly recommended in patients with autoimmune conditions as they may experience disease exacerbation following infection and carry a risk for severe SARS-CoV-2 courses [5, 6] . Recent reports suggest that several SARS-CoV-2 vaccines may induce platelet factor 4 (PF4) antibody-mediated thrombotic thrombocytopenia (VITT) 5-30 days following vaccination [7] [8] [9] . Similarly, cases of facial palsy, Guillain-Barré syndrome (GBS) and transverse myelitis have been documented following SARS-CoV-2 vaccinations [10] [11] [12] [13] [14] . infection was ruled out with polymerase chain reaction of endotracheal aspirates or nasopharyngeal swabs. Clinical, laboratory, radiological and outcome data were collected longitudinally. If patients were discharged from our institution, structured weekly telephone interviews were conducted with study participants or their legal guardians. Physicians involved in the outpatient care of participants were consulted for their longitudinal assessment. Descriptive analysis (frequencies, medians, ranges) of data was performed using SPSS version 27 (IBM). One VITT case was previously published [15] . Vaccination data including administered number of vaccine doses (first/second) and types from the Rhein-Neckar-Kreis (county), the main catchment area of our hospital, were provided by the State Ministry of Health. The number of individuals who only received their second dose during the inclusion period of this study was derived from the number of first doses administered 3 (BNT162b2), 4 (mRNA-1273) or 10 weeks (ChAdOx1) prior to the inclusion period (1 March 2021), assuming conventional dosing intervals, that every first was followed by a second shot with the same vaccine type, and that no individual moved between counties. The total number of individuals at risk was then estimated adding up individuals who at least received their first dose and those who received their second vaccine dose only. This estimate does not include individuals who were vaccinated 4 (BNT162b2) or 5 (mRNA-1273) to 6 weeks prior to the inclusion phase of this study and who could theoretically have fulfilled inclusion criteria by developing autoimmune diseases within 6 weeks after vaccination. However, it contains individuals vaccinated late during the inclusion phase of this study-when the number of weekly vaccinations was higher-and who may have developed autoimmunity only after the inclusion period of this study. The study was conducted in accordance with consensus-based clinical case reporting (CARE) guidelines [16] . autoimmune, cerebral venous sinus thrombosis, COVID-19, Guillain-Barré syndrome, multiple sclerosis, myelitis, myositis and cerebrospinal fluid (CSF) samples from our patients where available. Testing for PF4 antibodies in cases of cerebral venous sinus thrombosis (CVST) was performed as previously described [9, 15] . This study (S-373/2021) was approved by the Heidelberg University institutional review board. Written informed consent was obtained from all patients or their legal guardians. Patients with autoimmunity were involved in identifying research questions, defining relevant parameters, and in choosing structured telephone interviews for follow-up prior to institutional review board application. The results of this study will be disseminated in plain language following publication. During the inclusion phase of our study, 5978 patients (inpatient Table 1 . The characteristics of our cohort are summarized in Table 2 . Patients were predominantly female (ratio 3.2:1) and were vacci- Recent population-based studies found a significantly increased risk for PF4-antibody-mediated VITT with subsequent CVST following ChAdOx1 vaccinations [17, 18] . Similarly, analysing the vaccine adverse events reporting database the US Food and Drug Administration noted a potential association between Ad26.COV2.S vaccinations and GBS and revised the vaccine fact sheet accordingly [19] . Although the subject of ongoing research, these findings population-based studies [17, 18] . This observation might therefore also be attributed to variations of normal background incidences. Except for VITT, larger population-based studies-ideally with control groups-are therefore warranted to further investigate these findings. Many conditions found in temporal association with vaccinations in this study were previously reported as potential autoimmune sequels of SARS-CoV-2 infection with similar clinical and laboratory characteristics [27] [28] [29] [30] [31] [32] [33] [34] . Vaccines containing SARS-CoV-2 antigens may enhance autoimmunity by similar mechanisms including polyclonal or bystander activation, epitope spreading or molecular mimicry [35] . Alternatively, the inflammatory stimulus posed by vaccination may enhance autoimmunity in predisposed patients, particularly by driving pre-existing autoimmune pathways similar to pathogenesis of immune related adverse events following administration of immune checkpoint inhibitors [35] [36] [37] . In patients with new onset of autoimmune diseases, vaccination could have unmasked patients with previously asymptomatic autoimmunity. Lastly, although recent population-based studies linked SARS-CoV-2 vaccinations to VITT and GBS incidence was found to be in- COV2.S vaccinations [7] [8] [9] . In line with this clinical observation, a recent Scottish population-based study found an increased risk for VITT following administration of the ChAdOx1 but not the BNT162b2 vaccine [17] . Cases of GBS, which were previously described irrespective of the vaccine type, also only occurred after ChAdOx1 vaccinations whereas cases of optic neuritis and myositis were found following BNT162b2 vaccinations only. The interval from vaccination to onset of autoimmune responses resembled previously reported cases of PF4-antibody-mediated VITT, GBS, facial palsy and transverse myelitis which occurred 1-4 weeks after vaccination [7] [8] [9] 13, 14] . Laboratory findings upon diagnosis were remarkable for elevated C-reactive protein without other findings suggestive of infection in nine patients. This may correspond with excessive immune reaction following vaccination but must not necessarily characterize vaccinated persons with higher risk for autoimmune reactions. Thrombocyte counts were reduced in patients with VITT only in line with previous reports [7] [8] [9] . [36, 37] . In particular, in patients with CNS demyelinating disorders, which constituted the largest subgroup in our cohort, antibodies were rarely identified following immune checkpoint inhibitors [36, 37] . Treatment included administration of immunosuppressants in most cases. IVIGs were given to patients with GBS, and plasma exchange was chosen in the setting of severe autoimmunity or cases unresponsive to prior immunosuppressive therapy. As per recently published recommendations, two of three patients with VITT were therapeutically anticoagulated with argatroban and additionally received a 2-day treatment with high-dose IVIGs [9] . The latter had beneficial effects on thrombocyte counts and the clinical course of our patients as recently suggested by Bourguignon et al. [38] . Overall symptoms responded well to treatment including cases of VITT, which had a poor outcome in most previous case series [7] [8] [9] . Levels of acute-phase proteins corresponded well with clinical responses and may assist to monitor the disease course particularly in patients who require mechanical ventilation. According to our experience, vigilant inpatient or outpatient monitoring under continuous immunosuppressive treatment may allow administration of the second vaccine dose in selected cases of less severe autoimmune reactions. However, a recent prospective cohort study in solid organ transplant patients under immunosuppressive therapy found low antibody titres following vaccination in more than half of the patients [39] . Whilst correlation of antibody titres with vaccine efficacy is pending and thresholds are yet to be determined, lower titres could correspond to a shorter or less sufficient antiviral protection. Strategies such as longer dosing intervals or a third booster shot may improve antibody titres in immunocompromised individuals and warrant further investigation [40] . A limitation of our study is the cohort size although previous reports of VITT and GBS included an even smaller number of patients [7] [8] [9] . The single university centre design of our study may result in a selection bias. Individuals with more severe symptoms may have consulted our institution whereas others may have simply presented to their local healthcare providers. Whilst a temporal association is weigh the rather small risk of autoimmune complications [41] . In this study, the characteristics of a broad spectrum of neuro- The State Ministry of Health (Baden-Württemberg) is thanked for kindly providing SARS-CoV-2 vaccination data for the Rhein Dr Wagner-Wiening, Dr Gaile and Mr Falk who were involved in data curation are specifically thanked. Open access funding enabled and organized by ProjektDEAL Conceptualization (lead); data curation (lead) formal analysis (equal); investigation (lead); methodology (lead) Sofia Doubrovinskaia: Data curation (supporting); formal analysis (supporting); investigation (supporting) Christoph Mooshage: Data curation (supporting); formal analysis (supporting); investigation (supporting); writing-review and editing (supporting) Jan Purrucker: Data curation (supporting); investigation (supporting); writing-review and editing (supporting). Carmen Haubner: Data curation (supporting) investigation (supporting); writing-review and editing (supporting) Simon Nagel: Data curation (supporting); investigation (supporting); writing-review and editing (supporting). Brigitte Wildemann: Data curation (supporting) Data curation (supporting); formal analysis (supporting); investigation (supporting); writing-review and editing (supporting). W. Wick: Conceptualization (supporting); data curation (supporting) supervision (supporting); writing-review and editing (supporting) Conceptualization (lead); data curation (lead) formal analysis (lead); investigation (lead); methodology (lead); project administration (lead); writing-original draft (equal); writingreview and editing (lead) Martin Bendszus Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Perspective of patients with autoimmune diseases on COVID-19 vaccination Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of Patients with Multiple Sclerosis Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Thrombotic thrombocytopenia after Ad26.COV2.S vaccination Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Bell's palsy and SARS-CoV-2 vaccines Bell's palsy and SARS-CoV-2 vaccines-an unfolding story Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia The CARE guidelines: consensus-based clinical case reporting guideline development First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and haemorrhagic events in Scotland COVID-19 vaccine-associated cerebral venous thrombosis in Germany Coronavirus (COVID-19) Update The incidence of cerebral venous thrombosis Estimation of background incidence rates of Guillain-Barré syndrome in Germany-a retrospective cohort study with electronic healthcare data The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Incidence and prevalence of inflammatory myopathies: a systematic review Clinically isolated acute transverse myelitis: prognostic features and incidence Myositis as a manifestation of SARS-CoV-2 A case of limbic encephalitis associated with asymptomatic COVID-19 infection Myasthenia gravis associated with SARS-CoV-2 infection Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19 Peripheral facial nerve palsy associated with COVID-19 Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died Acute transverse myelitis after COVID-19 pneumonia Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Vaccines and autoimmunity Neurologic adverse events of immune checkpoint inhibitors Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients An interactive web-based dashboard to track COVID-19 in real time